drug_type
RELEVANT_DRUG
intervention_type
Therapeutic monoclonal antibody (biologic)
drug_description
An investigational anti-CD38 therapeutic monoclonal antibody administered intravenously (16 mg/kg weekly for 8 weeks) to deplete CD38-expressing long-lived plasma cells and plasmablasts, aiming to reduce pathogenic antiplatelet autoantibodies and improve platelet counts in refractory ITP.
nci_thesaurus_concept_id
C180505
nci_thesaurus_definition
A monoclonal antibody directed against the human cell surface glycoprotein ADP-ribosyl cyclase 1 (CD38), with potential antineoplastic activity. Upon administration, lumrotatug specifically targets and binds to CD38 expressed on tumor cells. This may trigger antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) and apoptosis, resulting in cell lysis and depletion of CD38-expressing tumor cells. In addition, lumrotatug inhibits the extracellular enzyme activity of CD38. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies. It plays an important role in the regulation of migration and receptor-mediated adhesion, as well as various cell functions through its multiple ecto- and endo-enzymatic activities.
drug_mesh_term
Antibodies, Monoclonal
drug_category
CYTOTOXIC ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Anti-CD38 monoclonal antibody that binds CD38 on long-lived plasma cells and plasmablasts, triggering ADCC, CDC, and ADCP to deplete these cells and reduce pathogenic antiplatelet autoantibodies; may also inhibit CD38 ectoenzyme activity.
drug_name
CM313
nct_id_drug_ref
NCT06199089